Welcome to our dedicated page for Health Catalyst news (Ticker: HCAT), a resource for investors and traders seeking the latest updates and insights on Health Catalyst stock.
Health Catalyst, Inc. (Nasdaq: HCAT) is a leading provider of data and analytics technology and services to healthcare organizations. Founded by healthcare veterans, the company specializes in building comprehensive data warehousing and process improvement solutions, aiming to significantly enhance healthcare delivery. Health Catalyst's innovative solutions are powered by its adaptive data architecture, which uses a late-binding bus model for agile and quick implementation.
The company operates primarily through two segments: Technology and Professional Services. The Technology segment is the key revenue driver, providing data platforms, analytics applications, and support services under cloud-based subscriptions, time-based licenses, and maintenance agreements. The Professional Services segment offers analytics, implementation, strategic advisory, outsourcing, and improvement services, enabling clients to maximize the utility of Health Catalyst's technological offerings.
Health Catalyst has recently gained recognition with several achievements:
- VitalCDM: Ranked number one in the Revenue Cycle - Chargemaster Management category of the 2024 Best in KLAS: Software & Services.
- MeasureAble™: Achieved ONC-Health IT 2015 Edition Certification, allowing its use for various quality reporting programs.
- Able Health Registry: Received QPP Qualified Registry approval for the 2024 performance year from CMS.
- Acquisition of Carevive Systems: Strengthened their capabilities in oncology data analytics, improving patient care and outcomes.
Financially, Health Catalyst continues to show promising trends, with forward-looking revenue and EBITDA guidance indicating growth. The company frequently updates its investors through quarterly earnings calls and reports, reflecting transparency and financial health.
Health Catalyst envisions a future where all healthcare decisions are data-informed, leveraging a cloud-based data platform encompassing over 100 million patient records and trillions of data points. This commitment to data-informed decision-making is at the core of its mission to drive measurable improvements in clinical, financial, and operational metrics for healthcare organizations.
For more information, visit the Health Catalyst Investor Relations page.
Health Catalyst, Inc. (HCAT) has announced a strategic partnership with Datavant to enhance research and clinical care through connected health data. This collaboration aims to reduce waste in patient recruitment for clinical trials by using tokenized, de-identified data within the Health Catalyst Research Network™. The partnership will facilitate data connectivity throughout the study life cycle, improving pre-trial feasibility, patient eligibility, and long-term safety analysis. Leaders from both companies emphasize the potential to broaden patient access and improve health outcomes through better data sharing.
Health Catalyst (NASDAQ: HCAT) reported a strong performance for Q3 2021, exceeding revenue and Adjusted EBITDA guidance. Key financial metrics show total revenue of $61.737 million, a 31% year-over-year increase, driven by 37% growth in technology revenue and 22% in professional services. Despite these gains, the company reported a 46% rise in net loss, reaching $40.014 million. Adjusted Technology Gross Profit increased 40% to $26.731 million, reflecting a 70% gross margin. The financial outlook remains cautiously optimistic.
Health Catalyst (Nasdaq: HCAT) will release its 2021 third quarter operating results on November 9, 2021, after market close. A conference call to discuss these results is scheduled for 5 p.m. E.T. the same day. Participants can join the call via phone or through a live audio webcast available on the company's investor relations website. Health Catalyst provides data and analytics technology to healthcare organizations, leveraging a cloud-based platform with data from over 100 million patient records to drive improvements in clinical, financial, and operational outcomes.
Health Catalyst (Nasdaq: HCAT) announced its participation in the Cantor Global Healthcare Conference on September 30, 2021, featuring a fireside chat at 1:20 p.m. ET. The company's CFO, Bryan Hunt, and SVP of Investor Relations, Adam Brown, will represent the organization. Health Catalyst provides data and analytics technology and services aimed at enhancing healthcare performance. Its cloud-based platform leverages data from over 100 million patient records to drive measurable improvements in clinical, financial, and operational areas.
Health Catalyst (Nasdaq: HCAT) announced the addition of Matt Revis to its leadership team, effective August 31, 2021. Revis, previously President and COO of Twistle, will report to COO Paul Horstmeier. He aims to enhance patient engagement technology for better healthcare outcomes. Prior to Twistle, Revis held significant roles at Jibo and Nuance Communications, contributing to product innovation and healthcare strategy. CEO Dan Burton praised Revis's leadership in advancing Health Catalyst's mission of measurable healthcare improvement.
Twistle by Health Catalyst (Nasdaq: HCAT) is enhancing access to obstetric services in Northeastern New Mexico through its partnership with the Rural OB Access & Maternal Services (ROAMS) initiative. This program utilizes Twistle's patient engagement technology to connect patients across five rural communities, allowing direct communication with care teams via mobile devices. The initiative aims to improve maternal health outcomes by reducing barriers such as travel and enhancing monitoring of conditions like gestational diabetes. Twistle's platform is HIPAA-compliant, offering personalized support and education to pre- and post-partum patients.
Health Catalyst has announced a multi-year partnership with Oklahoma Heart Hospital (OHH) aimed at enhancing revenue cycle analytics and performance. The partnership will utilize Health Catalyst's Data Operating System (DOS) platform to improve operational and clinical processes. OHH seeks to drive transparency in care costs and empower clinicians with actionable data. The collaboration is expected to position OHH for ongoing success in a changing healthcare landscape, leveraging Health Catalyst's comprehensive analytics solutions to identify trends and enhance patient care.
Health Catalyst announced a public offering of 4,245,283 shares of common stock at $53.00 per share, projected to raise approximately $225.0 million in gross proceeds. A 30-day option allows underwriters to purchase an additional 636,792 shares. The offering, led by J.P. Morgan, Goldman Sachs, and Evercore, is expected to close around August 13, 2021, pending customary conditions. This capital will support the company’s goals in healthcare data and analytics.
Health Catalyst has announced a public offering of $225 million in common stock, all of which will be offered by the company itself. The offering is contingent on market conditions and may include an option for underwriters to purchase an additional $33.75 million in shares within 30 days. J.P. Morgan, Goldman Sachs, and Evercore act as joint bookrunning managers for the offering. The public offering is conducted under an effective shelf registration and associated prospectus filed with the SEC.
Twistle by Health Catalyst (Nasdaq: HCAT) will participate in the HIMSS21 Global Conference, scheduled for August 9-13, 2021, in Las Vegas. Twistle plans to showcase its secure patient communication platform at booth #C437-38, highlighting how it can reduce health disparities and improve patient engagement. Attendees can witness live demonstrations and learn about initiatives like the #pinksocks movement, emphasizing community connection. A presentation by Tom Burton will discuss the ROI of patient engagement strategies implemented by Providence, aimed at enhancing surgical outcomes and reducing complications.